---
title: 'Director, Clinical Procurement at Generate Biomedicines'
canonical: 'https://feeny.ai/job/director-clinical-procurement-generate-biomedicines-remote-qakj30d4dthm'
type: 'job'
last_seen: '2026-10-30'
---

# Director, Clinical Procurement at Generate Biomedicines

- **Company:** Generate Biomedicines
- **Location:** Remote
- **Compensation:** $186k–$260k
- **Work type:** remote
- **Posted:** 2026-10-28
- **Last confirmed live:** 2026-10-30
- **Apply:** https://generatebiomedicines.com/open-positions?gh_jid=4725187006

## Job description

The Role:

We are seeking a Director of Clinical Procurement to lead sourcing and supplier management for our late-stage clinical program. Reporting to the Head of Global Clinical Operations, this leader will shape clinical procurement strategy, guide selection and oversight of clinical vendors, and help ensure the program has the capabilities and capacity it needs to execute successfully across regions.

The Director will work closely with Clinical Operations, Central Procurement, Finance, Legal, Quality, and other cross-functional partners. The role combines strategic planning with hands-on leadership of complex sourcing decisions, contract negotiations, supplier performance, and clinical procurement activities within Generate’s established procurement governance framework..

Here's how you will contribute:

- Develop and lead the clinical procurement strategy aligned with Generate’s broader procurement strategy, for the late-stage program, aligned with clinical development plans, study timelines, and operating priorities.
- Partner with Clinical Operations and functional leaders to forecast vendor needs, assess sourcing options, and plan procurement activities across the program lifecycle.
- Lead clinical vendor sourcing and evaluation processes and develop selection recommendations with Clinical Operations and relevant functional owners, following Generate’s established procurement review and approval requirements , including CROs, central laboratories, imaging providers, eCOA and technology vendors, logistics providers, and other trial-related suppliers.
- Coordinate with the Procurement Department on suppliers and agreements that serve both clinical and other business functions.
- Structure and run competitive processes, , vendor evaluations, due diligence, and selection recommendations.
- Lead commercial negotiations and contracting for clinical services in partnership with Procurement Legal, Finance, and relevant functional owners; seek value while supporting quality, delivery, and continuity of supply.
- Establish clear scopes of work, budgets, service expectations, change controls, and performance measures for key suppliers.
- Build effective vendor governance with Clinical Operations, including business reviews, issue escalation, corrective actions, and performance improvement plans.
- Monitor supplier capacity, financial health, delivery risks, and dependencies that could affect study execution; develop mitigation and contingency plans.
- Support clinical budget development, cost analysis, accrual forecasting, and ongoing spend management in partnership with Finance and study teams.
- Maintain procurement processes and documentation consistent with company policies, applicable regulations, and quality requirements.
- Contribute to process improvements, procurement reporting, and practical guidance for teams engaging clinical suppliers.
- Maintain regular alignment with the Senior Director, Procurement and Strategic Sourcing on clinical sourcing priorities, negotiation strategies, supplier risks, and procurement policy matters; escalate issues through established clinical and procurement governance channels.
- Lead and develop clinical procurement team members or matrixed project resources as the function and program needs evolve, coordinating with the Procurement Department on shared resources.

The Ideal Candidate will have:

- Bachelor’s degree in business, supply chain, life sciences, or a related field; advanced degree or relevant professional certification is a plus.
- 12+ years of relevant experience in clinical procurement, strategic sourcing, or vendor management within the biopharmaceutical or clinical research industry.
- 5+ years of experience leading teams, major sourcing initiatives, or complex cross-functional programs.
- Experience supporting global, late-stage clinical development programs, including complex, multi-country studies.
- Demonstrated success leading vendor selection, commercial negotiations, and contract management for clinical services.
- Working knowledge of clinical trial operations, clinical service provider models, and the needs of cross-functional study teams.
- Experience managing supplier performance, budgets, risks, and escalations across multiple vendors and workstreams.
- Strong financial and analytical skills, including the ability to assess proposals, pricing structures, forecasts, and cost drivers.
- Familiarity with regulated clinical development environments and relevant quality and compliance expectations.
- Excellent communication and negotiation skills, with the ability to influence senior stakeholders and build productive supplier relationships.
- Proven ability to lead through collaboration, prioritize competing demands, and deliver in a dynamic environment.

Who Will Love This Job:

The successful candidate is a strategic and practical leader who can move between program-level planning and detailed commercial decisions. They bring sound judgment, build trust across functions, and keep procurement focused on enabling high-quality, timely clinical execution.

About Generate:Biomedicines

We are a clinical-stage generative biology company pioneering the AI revolution in drug design and development. We are advancing a new approach to drug creation—one grounded in the ability to design proteins with defined biological intent. By integrating machine learning with large-scale experimentation, this approach aims to reduce the uncertainty, time, and cost associated with developing protein-based medicines.

Founded in 2018, we are advancing a growing pipeline of clinical and preclinical programs across multiple disease areas and protein modalities. By unifying computational design and clinical development within a single operating model, we translate this approach into clinical-stage programs and are leading a shift from traditional drug discovery toward systematic drug generation.

At Generate:Biomedicines, we collaborate across disciplines in new ways to invent and innovate. We bring diverse perspectives to a shared goal of delivering better medicines to patients in need, faster, guided by our values and leadership behaviors.

Generate:Biomedicines is committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

Recruitment & Staffing Agencies: Generate:Biomedicines does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Generate:Biomedicines or its employees is strictly prohibited unless contacted directly by the Company’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Generate:Biomedicines and the Company will not owe any referral or other fees with respect thereto.

## #LI-RT1

Compensation: The base salary range provided reflects our current estimate of what we anticipate paying for this position. Your actual base salary will be based on several factors, including job-related skills, experience, internal equity, relevant education or training, and market dynamics. In addition, you will be eligible for an annual bonus, equity compensation, and a competitive benefits package.

Per Year Salary Range $186,000—$260,000 USD

## About Generate Biomedicines

## Company Overview
- **One-liner**: Generate Biomedicines is a clinical-stage generative biology company pioneering the use of machine learning to design and develop protein-based medicines on demand.
- **Entity Type**: Public (ticker: GBIO)
- **Headquarters**: Somerville, Massachusetts, USA (Boynton Yards and Andover locations)
- **Founded**: 2018
- **Founders**: Gevorg Grigoryan, Daria Hazuda, and others

## Core Business
- **Primary industry**: Biotechnology / Drug Discovery & Development
- **Target customers**: B2B (pharmaceutical partners) and patients (via clinical programs)
- **Mission statement**: "We don’t discover medicines—we design them," with a belief that speed is a moral obligation to patients.

## Products & Services
- **[Generate Platform™]**: An integrated computational and biohardware innovation stack that uses generative biology to design proteins with defined biological intent. It can generate up to a billion designed variants per cycle with cycle times as fast as ~8 days.
- **[GB-0895 (Anti-TSLP Antibody)]**: A next-generation anti-TSLP monoclonal antibody for severe asthma and COPD, currently in global Phase 3 trials. Designed for ultra-high affinity (106 fM binding, 20x improvement over tezepelumab) and an extended half-life (98 days, longest known among TSLP-targeting therapies), enabling twice-yearly subcutaneous dosing.
- **[GB-5267 (MUC-16 Armored CAR-T)]**: A cell therapy candidate for metastatic ovarian cancer, expected to enter Phase 1 in 1H26.
- **[GB-4362 (Free MMAE Toxin Neutralizer)]**: A first-in-class neutralizer designed for combination with MMAE-based antibody-drug conjugates (ADCs), with Phase 1 initiation in bladder cancer expected 1H26.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed; IPO in February 2026 raised net proceeds of approximately $370 million.
- **Key Metric**: $221.5 million cash balance at YE 2025, plus ~$370 million from IPO (early 2026).
- **Notable Investors/Partners**: Strategic collaborations with Amgen, Novartis, MD Anderson Cancer Center, and Roswell Park Comprehensive Cancer Center.
- **Growth Signals**: 5 clinical-stage programs enabled by the platform; initiated global Phase 3 studies for GB-0895; operating out of 140k+ square feet of lab and office space; has studied millions of proteins and generated 42,000 proteins built and tested.

## Competitive Advantages
- **Fully integrated computational-biohardware loop**: Machine learning drives generative design, which feeds directly into high-throughput experimentation (including proprietary CryoEM with four of the best microscopes in the world), and results continuously train the AI system — a "living feedback loop" that compounds over time.
- **Multimodal platform**: Can generate candidates across antibodies, CAR-T, and other protein modalities from a single core technology, enabling a pipeline that covers both immunology and oncology.
- **Record speed and scale**: Capable of generating up to a billion designed variants in ~8-day cycles, dramatically reducing the time and cost traditionally associated with drug discovery.
- **First-mover in next-gen anti-TSLP**: First known next-generation anti-TSLP antibody to enter the clinic (GB-0895) with a differentiated half-life profile that could enable twice-yearly dosing, a significant competitive edge in a large market.

## Strategic Focus
- **Clinical execution**: Advancing GB-0895 through global Phase 3 trials in severe asthma (with data in 2H27/1H28) and initiating late-stage development in COPD.
- **Pipeline expansion**: Moving GB-5267 (CAR-T) and GB-4362 (ADC neutralizer) into Phase 1 in 2026, expanding the platform's therapeutic scope.
- **Platform scaling**: Continuing to refine the generative biology engine to unlock new modalities and therapeutic areas, while deepening existing strategic collaborations with major pharma partners.
- **Organizational growth**: Building out the team across computational, wet-lab, clinical, and operational functions to support the growing pipeline.

## Why Work Here
- **Mission-driven**: The company is explicit that "speed is not just a competitive advantage—it’s a moral obligation." Employees are directly involved in designing drugs rather than discovering them, with a focus on getting treatments to patients faster.
- **Interdisciplinary culture**: The company emphasizes true integration across machine learning, biological engineering, and medicine. As stated on their site, "We are a close-knit group of cross-disciplinary experts... each conversant in one another’s fields, working together to create a new one."
- **Cutting-edge technology**: Access to unique computational and biohardware infrastructure, including "the four best CryoEM microscopes in the world" and a high-throughput experimental loop that powers AI training in real-time.
- **Values-driven leadership**: Explicit leadership behaviors include "value the knowledge we gain more than the knowledge we have," "bring creativity, tenacity, and ingenuity to every challenge," and "hold oneself and others to an obligation to dissent."
- **Hybrid/office policy**: Not explicitly stated, but the company operates large physical facilities in Somerville and Andover, MA, and offers free parking, monthly subway passes, or subsidized commuter rail passes, suggesting a significant on-site expectation.
- **Comprehensive benefits**: Competitive pay, employee stock option plan, health/vision/dental insurance, long- and short-term disability, life insurance, EAP, retirement savings, paid parental/adoption/caregiver leave, free weekly lunch, and stocked kitchen.
- **Growth trajectory**: As a newly public company with a cash-rich balance sheet and multiple catalysts over the next 12–24 months, the company offers significant career growth potential for those who want to be part of building a "transcendent company" that redefines an industry.

## Sources
1. [generatebiomedicines.com](https://generatebiomedicines.com/)
2. [generatebiomedicines.com/careers](https://generatebiomedicines.com/careers)
3. [generatebiomedicines.com/about-us](https://generatebiomedicines.com/about-us)
4. [investors.generatebiomedicines.com](https://investors.generatebiomedicines.com/)
5. [Non-Confidential Overview (April 2026)](https://investors.generatebiomedicines.com/wp-content/uploads/2026/04/Generate-Biomedicines-Non-Confidential-Overview_April-2026-1.pdf)

## Other roles at Generate Biomedicines

- [Senior Clinical Trial Manager](https://feeny.ai/job/senior-clinical-trial-manager-generate-biomedicines-remote-c0vrxewkybbt)
- [Senior Manager, Vendor Management](https://feeny.ai/job/senior-manager-vendor-management-generate-biomedicines-remote-321ee8qrkrzj)
- [Senior Director, Clinical Operations Business & Excellence](https://feeny.ai/job/senior-director-clinical-operations-business-excellence-generate-biomedicines-42e1kvgmzdf6)
- [Senior Scientist I, Computational Protein Design](https://feeny.ai/job/senior-scientist-i-computational-protein-design-generate-biomedicines-somerville-caa239jvj23x) — Somerville, MA
- [Scientist I, Computational Protein Design](https://feeny.ai/job/scientist-i-computational-protein-design-generate-biomedicines-somerville-6n26sf6x6wva) — Somerville, MA
- [Scientist II, Functional Bioassays & High Throughput Screening](https://feeny.ai/job/scientist-ii-functional-bioassays-high-throughput-screening-generate-ajjehf28b7v6) — Somerville, MA
- [Senior Scientist I, Protein Analytics & Biophysics](https://feeny.ai/job/senior-scientist-i-protein-analytics-biophysics-generate-biomedicines-somerville-84zvsqcb2gzh) — Somerville, MA
- [Principal Scientist, Target Binding](https://feeny.ai/job/principal-scientist-target-binding-generate-biomedicines-somerville-nst4sw7htmp7) — Somerville, MA
- [Scientist I, Synthetic Biology](https://feeny.ai/job/scientist-i-synthetic-biology-generate-biomedicines-somerville-xfvg8ftyvq3y) — Somerville, MA
- [Associate Director, Biotherapeutic Production and Characterization](https://feeny.ai/job/associate-director-biotherapeutic-production-and-characterization-generate-vhxshbh7baa1) — Somerville, MA